On August 3, Stryker rose 3.99% in regular trading, trading at approximately $334.23/share, with turnover of $103 million. The rebound follows a sharp post-earnings selloff that saw shares drop over 8% after the company reported Q2 results on July 30.

While Stryker's Q2 adjusted EPS of $3.69 beat consensus of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, its core MedSurg and Neurotechnology segment posted revenue of $3.6 billion, missing the $3.72 billion expectation. Additionally, full-year adjusted EPS guidance was only narrowed to $14.95-$15.10 from $14.90-$15.10, a minimal raise that disappointed investors given the strong Q2 beat. After consecutive sessions of selling pressure, the stock is now rebounding alongside broad healthcare equipment sector strength, with Intuitive Surgical up 6.02%, Boston Scientific up 3.98%, and DexCom up 3.98%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)